Under one in 10 patients eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it issues its inaugural advice on the drugs.
Considering over a billion individuals worldwide currently classified as obese, it is urging increased and just access to these injectable treatments.
Based on estimates, more than two billion could be obese by 2030 unless action is taken.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be treated with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major barriers to universal availability to the injections that can assist patients in reducing substantial body mass, explains the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic scenario, the manufacturing of these medications could only cover about 100 million people – less than 10% of eligible patients, per the health organization.
The guideline calls on countries and companies to expand access, via approaches such as licensing agreements.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Operate
These medications replicate a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so users reduce food intake.
People usually see weight reduction within a few weeks of beginning the regular doses.
Research points to people may put most of the weight back on within a year of stopping the drug, when their typical appetite return.
To be carrying excess weight raises your chance for contracting health problems, like diabetes, heart disease, stroke, and specific cancers.
Obesity affects people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
